Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Jul 13. pii: S0302-2838(18)30445-7. doi: 10.1016/j.eururo.2018.06.020. [Epub ahead of print]

PMID:
30049486
2.

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM Jr, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W, Risbridger GP, Gronberg H, Aly M, Nordström T, Pharoah P, Pashayan N, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Albanes D, Weinstein S, Wolk A, Håkansson N, West CML, Dunning AM, Burnet N, Mucci LA, Giovannucci E, Andriole GL, Cussenot O, Cancel-Tassin G, Koutros S, Beane Freeman LE, Sorensen KD, Orntoft TF, Borre M, Maehle L, Grindedal EM, Neal DE, Donovan JL, Hamdy FC, Martin RM, Travis RC, Key TJ, Hamilton RJ, Fleshner NE, Finelli A, Ingles SA, Stern MC, Rosenstein BS, Kerns SL, Ostrer H, Lu YJ, Zhang HW, Feng N, Mao X, Guo X, Wang G, Sun Z, Giles GG, Southey MC, MacInnis RJ, FitzGerald LM, Kibel AS, Drake BF, Vega A, Gómez-Caamaño A, Szulkin R, Eklund M, Kogevinas M, Llorca J, Castaño-Vinyals G, Penney KL, Stampfer M, Park JY, Sellers TA, Lin HY, Stanford JL, Cybulski C, Wokolorczyk D, Lubinski J, Ostrander EA, Geybels MS, Nordestgaard BG, Nielsen SF, Weischer M, Bisbjerg R, Røder MA, Iversen P, Brenner H, Cuk K, Holleczek B, Maier C, Luedeke M, Schnoeller T, Kim J, Logothetis CJ, John EM, Teixeira MR, Paulo P, Cardoso M, Neuhausen SL, Steele L, Ding YC, De Ruyck K, De Meerleer G, Ost P, Razack A, Lim J, Teo SH, Lin DW, Newcomb LF, Lessel D, Gamulin M, Kulis T, Kaneva R, Usmani N, Singhal S, Slavov C, Mitev V, Parliament M, Claessens F, Joniau S, Van den Broeck T, Larkin S, Townsend PA, Aukim-Hastie C, Dominguez MG, Castelao JE, Martinez ME, Roobol MJ, Jenster G, van Schaik RHN, Menegaux F, Truong T, Koudou YA; Profile Study, Xu J, Khaw KT, Cannon-Albright L, Pandha H, Michael A, Thibodeau SN, McDonnell SK, Schaid DJ, Lindstrom S, Turman C, Ma J, Hunter DJ, Riboli E, Siddiq A, Canzian F, Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Cui Z, Kraft P; Australian Prostate Cancer BioResource (APCB); IMPACT Study; Canary PASS Investigators; Breast and Prostate Cancer Cohort Consortium (BPC3); PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Cancer of the Prostate in Sweden (CAPS); Prostate Cancer Genome-wide Association Study of Uncommon Susceptibility Loci (PEGASUS); Genetic Associations and Mechanisms in Oncology (GAME-ON)/Elucidating Loci Involved in Prostate Cancer Susceptibility (ELLIPSE) Consortium, Amos CI, Conti DV, Easton DF, Wiklund F, Chanock SJ, Henderson BE, Kote-Jarai Z, Haiman CA, Eeles RA.

Nat Genet. 2018 Jul;50(7):928-936. doi: 10.1038/s41588-018-0142-8. Epub 2018 Jun 11.

PMID:
29892016
3.

Enduring epigenetic landmarks define the cancer microenvironment.

Pidsley R, Lawrence MG, Zotenko E, Niranjan B, Statham A, Song J, Chabanon RM, Qu W, Wang H, Richards M, Nair SS, Armstrong NJ, Nim HT, Papargiris M, Balanathan P, French H, Peters T, Norden S, Ryan A, Pedersen J, Kench J, Daly RJ, Horvath LG, Stricker P, Frydenberg M, Taylor RA, Stirzaker C, Risbridger GP, Clark SJ.

Genome Res. 2018 May;28(5):625-638. doi: 10.1101/gr.229070.117. Epub 2018 Apr 12.

4.

Estrogen receptor subtypes dictate the proliferative nature of the mammary gland.

Dall GV, Hawthorne S, Seyed-Razavi Y, Vieusseux J, Wu W, Gustafsson JA, Byrne D, Murphy L, Risbridger GP, Britt KL.

J Endocrinol. 2018 Jun;237(3):323-336. doi: 10.1530/JOE-17-0582. Epub 2018 Apr 10.

PMID:
29636363
5.

Preclinical Models of Prostate Cancer: Patient-Derived Xenografts, Organoids, and Other Explant Models.

Risbridger GP, Toivanen R, Taylor RA.

Cold Spring Harb Perspect Med. 2018 Aug 1;8(8). pii: a030536. doi: 10.1101/cshperspect.a030536. Review.

PMID:
29311126
6.

Role of activin C in normal ovaries and granulosa cell tumours of mice and humans.

Reader KL, Marino FE, Nicholson HD, Risbridger GP, Gold EJ.

Reprod Fertil Dev. 2017 Dec 6. doi: 10.1071/RD17250. [Epub ahead of print]

PMID:
29207252
7.

Novel imaging of the prostate reveals spontaneous gland contraction and excretory duct quiescence together with different drug effects.

Kügler R, Mietens A, Seidensticker M, Tasch S, Wagenlehner FM, Kaschtanow A, Tjahjono Y, Tomczyk CU, Beyer D, Risbridger GP, Exintaris B, Ellem SJ, Middendorff R.

FASEB J. 2018 Mar;32(3):1130-1138. doi: 10.1096/fj.201700430R. Epub 2018 Jan 3.

PMID:
29089445
8.

Mysterious inhibitory cell regulator investigated and found likely to be secretogranin II related.

Hart JE, Clarke IJ, Risbridger GP, Ferneyhough B, Vega-Hernández M.

PeerJ. 2017 Oct 13;5:e3833. doi: 10.7717/peerj.3833. eCollection 2017.

9.

Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.

Porter LH, Hashimoto K, Lawrence MG, Pezaro C, Clouston D, Wang H, Papargiris M, Thorne H, Li J; kConFab, Ryan A, Norden S, Moon D, Bolton DM, Sengupta S, Frydenberg M, Murphy DG, Risbridger GP, Taylor RA.

BJU Int. 2018 Jun;121(6):971-978. doi: 10.1111/bju.14043. Epub 2017 Oct 26.

PMID:
28977728
10.

Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate.

Lee SN, Chakrabarty B, Wittmer B, Papargiris M, Ryan A, Frydenberg M, Lawrentschuk N, Middendorff R, Risbridger GP, Ellem SJ, Exintaris B.

Sci Rep. 2017 Aug 31;7(1):10150. doi: 10.1038/s41598-017-07861-x.

11.

A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.

Sackmann Sala L, Boutillon F, Menara G, De Goyon-Pélard A, Leprévost M, Codzamanian J, Lister N, Pencik J, Clark A, Cagnard N, Bole-Feysot C, Moriggl R, Risbridger GP, Taylor RA, Kenner L, Guidotti JE, Goffin V.

J Pathol. 2017 Sep;243(1):51-64. doi: 10.1002/path.4924. Epub 2017 Jul 28.

PMID:
28603917
12.

Kallikrein-related peptidase 4 induces cancer-associated fibroblast features in prostate-derived stromal cells.

Kryza T, Silva LM, Bock N, Fuhrman-Luck RA, Stephens CR, Gao J, Samaratunga H; Australian Prostate Cancer BioResource, Lawrence MG, Hooper JD, Dong Y, Risbridger GP, Clements JA.

Mol Oncol. 2017 Oct;11(10):1307-1329. doi: 10.1002/1878-0261.12075. Epub 2017 Aug 10.

13.

Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.

Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA.

Eur Urol. 2017 Oct;72(4):492-495. doi: 10.1016/j.eururo.2017.03.013. Epub 2017 Mar 22. Review.

PMID:
28342640
14.

SCA-1 Labels a Subset of Estrogen-Responsive Bipotential Repopulating Cells within the CD24+ CD49fhi Mammary Stem Cell-Enriched Compartment.

Dall GV, Vieusseux JL, Korach KS, Arao Y, Hewitt SC, Hamilton KJ, Dzierzak E, Boon WC, Simpson ER, Ramsay RG, Stein T, Morris JS, Anderson RL, Risbridger GP, Britt KL.

Stem Cell Reports. 2017 Feb 14;8(2):417-431. doi: 10.1016/j.stemcr.2016.12.022. Epub 2017 Jan 26.

15.

The Evolving Narrative of DNA Repair Gene Defects: Distinguishing Indolent from Lethal Prostate Cancer.

Murphy DG, Risbridger GP, Bristow RG, Sandhu S.

Eur Urol. 2017 May;71(5):748-749. doi: 10.1016/j.eururo.2017.01.025. Epub 2017 Jan 26. No abstract available.

PMID:
28131466
16.

Over-Expression of Activin-βC Is Associated with Murine and Human Prostate Disease.

Ottley EC, Reader KL, Lee K, Marino FE, Nicholson HD, Risbridger GP, Gold E.

Horm Cancer. 2017 Apr;8(2):100-107. doi: 10.1007/s12672-017-0283-8. Epub 2017 Jan 23.

PMID:
28116672
17.

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.

Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.

Nat Commun. 2017 Jan 9;8:13671. doi: 10.1038/ncomms13671.

18.

The prognostic value of stromal FK506-binding protein 1 and androgen receptor in prostate cancer outcome.

Leach DA, Trotta AP, Need EF, Risbridger GP, Taylor RA, Buchanan G.

Prostate. 2017 Feb;77(2):185-195. doi: 10.1002/pros.23259. Epub 2016 Oct 8.

PMID:
27718274
19.

Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling.

Pidsley R, Zotenko E, Peters TJ, Lawrence MG, Risbridger GP, Molloy P, Van Djik S, Muhlhausler B, Stirzaker C, Clark SJ.

Genome Biol. 2016 Oct 7;17(1):208.

20.

A community-based model of rapid autopsy in end-stage cancer patients.

Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, Devereux L, O'Brien P, Gunawardena S, Hampson C, Strachan K, Jaravaza RD, Francis V, Young G, Ranson D, Samaranayake R, Stevens D, Boyle S, Fedele C, Topp M, Ho G, Teo ZL, Taylor RA, Papargiris MM, Lawrence MG, Wang H, Risbridger GP, Haynes NM, Medon M, Johnstone RW, Vidacs E, Arnau GM, Vergara IA, Papenfuss AT, McArthur G, Waring P, Carvosso S, Angel C, Gyorki D, Solomon B, Mitchell G, Shanley S, Francis PA, Dawson SJ, Haffenden A, Tidball E, Volchek M, Pyman J, Madadin M, Leditschke J, Cordner S; Melbourne Melanoma Project; Australian Ovarian Cancer Study Group (AOCS); Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Shackleton M, Bowtell DD.

Nat Biotechnol. 2016 Oct;34(10):1010-1014. doi: 10.1038/nbt.3674. Epub 2016 Sep 12. No abstract available.

PMID:
27617737
21.

A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.

El-Hoss J, Jing D, Evans K, Toscan C, Xie J, Lee H, Taylor RA, Lawrence MG, Risbridger GP, MacKenzie KL, Sutton R, Lock RB.

Oncotarget. 2016 Sep 13;7(37):60475-60490. doi: 10.18632/oncotarget.11125.

22.

The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.

Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, Drygin D, Clark AK, Porter L, Pedersen J, Sandhu S, Risbridger GP, Pearson RB, Hannan RD, Furic L.

Clin Cancer Res. 2016 Nov 15;22(22):5539-5552. doi: 10.1158/1078-0432.CCR-16-0124. Epub 2016 Aug 2.

23.

Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts.

Lo JC, Clark AK, Ascui N, Frydenberg M, Risbridger GP, Taylor RA, Watt MJ.

Oncotarget. 2016 Jul 26;7(30):47650-47662. doi: 10.18632/oncotarget.10258.

24.

Patient-Derived Prostate Cancer: from Basic Science to the Clinic.

Risbridger GP, Taylor RA.

Horm Cancer. 2016 Aug;7(4):236-40. doi: 10.1007/s12672-016-0266-1. Epub 2016 May 13. Review.

PMID:
27177552
25.

Enhancing active surveillance of prostate cancer: the potential of exercise medicine.

Galvão DA, Taaffe DR, Spry N, Gardiner RA, Taylor R, Risbridger GP, Frydenberg M, Hill M, Chambers SK, Stricker P, Shannon T, Hayne D, Zopf E, Newton RU.

Nat Rev Urol. 2016 May;13(5):258-65. doi: 10.1038/nrurol.2016.46. Epub 2016 Mar 8. Review.

PMID:
26954333
26.

Editorial: The Future of Our Basic Science and Scientists.

Risbridger GP.

Mol Endocrinol. 2015 Dec;29(12):1673-4. doi: 10.1210/me.2015-1284. No abstract available.

27.

Erratum: Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.

Leach DA, Need EF, Toivanen R, Trotta AP, Palethorpe HM, Tamblyn DJ, Kopsaftis T, England GM, Smith E, Drew PA, Pinnock CB, Lee P, Holst J, Risbridger GP, Chopra S, DeFranco DB, Taylor RA, Buchanan G.

Oncotarget. 2015 Nov 3;6(34):36923. doi: 10.18632/oncotarget.6263. No abstract available.

28.

Prostate cancer: Novel xenografts in mice--a new wave of preclinical models.

Risbridger GP.

Nat Rev Urol. 2015 Oct;12(10):540-1. doi: 10.1038/nrurol.2015.198. Epub 2015 Aug 18. No abstract available.

PMID:
26282212
29.

Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.

Lawrence MG, Pook DW, Wang H, Porter LH, Frydenberg M, Kourambas J, Appu S, Poole C, Beardsley EK, Ryan A, Norden S, Papargiris MM, Risbridger GP, Taylor RA.

Prostate. 2015 Sep;75(13):1475-83. doi: 10.1002/pros.23039. Epub 2015 Jul 14.

PMID:
26177841
30.

Pro-tumorigenic role of ERα in prostate cancer cells.

Furic L, Lawrence MG, Risbridger GP.

Aging (Albany NY). 2015 Jun;7(6):356-7. No abstract available.

PMID:
26143334
Free PMC Article
31.

Convergence of regenerative medicine and synthetic biology to develop standardized and validated models of human diseases with clinical relevance.

Hutmacher DW, Holzapfel BM, De-Juan-Pardo EM, Pereira BA, Ellem SJ, Loessner D, Risbridger GP.

Curr Opin Biotechnol. 2015 Dec;35:127-32. doi: 10.1016/j.copbio.2015.06.001. Epub 2015 Jun 26. Review.

PMID:
26121082
32.

Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome.

Leach DA, Need EF, Toivanen R, Trotta AP, Palethorpe HM, Tamblyn DJ, Kopsaftis T, England GM, Smith E, Drew PA, Pinnock CB, Lee P, Holst J, Risbridger GP, Chopra S, DeFranco DB, Taylor RA, Buchanan G.

Oncotarget. 2015 Jun 30;6(18):16135-50. Erratum in: Oncotarget. 2015 Nov 3;6(34):36923. Palenthorpe, Helen M [Corrected to Palethorpe, Helen M].

33.

Human cell lines as tools of our trade: "laying it on the (cell) line".

Risbridger GP.

Mol Endocrinol. 2015 Jan;29(1):1-2. doi: 10.1210/me.2014-1376. No abstract available.

34.

Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity.

Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R, Watt MJ, Taylor RA, Humbert P, Topisirovic I, Larsson O, Risbridger GP, Furic L.

Oncotarget. 2015 Jan 20;6(2):604-16.

35.

Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.

Altimari JM, Niranjan B, Risbridger GP, Schweiker SS, Lohning AE, Henderson LC.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):4948-53. doi: 10.1016/j.bmcl.2014.09.036. Epub 2014 Sep 19.

PMID:
25301770
36.

Sex specific retinoic acid signaling is required for the initiation of urogenital sinus bud development.

Bryant SL, Francis JC, Lokody IB, Wang H, Risbridger GP, Loveland KL, Swain A.

Dev Biol. 2014 Nov 15;395(2):209-17. doi: 10.1016/j.ydbio.2014.09.016. Epub 2014 Sep 27.

37.

Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM.

Eur Urol. 2015 Mar;67(3):496-503. doi: 10.1016/j.eururo.2014.08.007. Epub 2014 Aug 22.

PMID:
25154392
38.

A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment.

Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, Pook D, Pedersen J, Cawsey B, Trotta A, Need E, Buchanan G, Risbridger GP.

J Pathol. 2014 Sep;234(1):86-98. doi: 10.1002/path.4386. Epub 2014 Jul 9.

PMID:
25042571
39.

In vitro modeling of the prostate cancer microenvironment.

Ellem SJ, De-Juan-Pardo EM, Risbridger GP.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:214-21. doi: 10.1016/j.addr.2014.04.008. Epub 2014 May 9. Review.

PMID:
24816064
40.

Preliminary investigations into triazole derived androgen receptor antagonists.

Altimari JM, Niranjan B, Risbridger GP, Schweiker SS, Lohning AE, Henderson LC.

Bioorg Med Chem. 2014 May 1;22(9):2692-706. doi: 10.1016/j.bmc.2014.03.018. Epub 2014 Apr 1.

PMID:
24726305
41.

Are we disrupted?

Risbridger GP.

Endocr Relat Cancer. 2014 Mar 19;21(2):E1-2. doi: 10.1530/ERC-14-0115. Print 2014 Apr. No abstract available.

PMID:
24648501
42.

Aromatase transgenic upregulation modulates basal cardiac performance and the response to ischemic stress in male mice.

Bell JR, Bernasochi GB, Varma U, Boon WC, Ellem SJ, Risbridger GP, Delbridge LM.

Am J Physiol Heart Circ Physiol. 2014 May;306(9):H1265-74. doi: 10.1152/ajpheart.00012.2014. Epub 2014 Mar 7.

43.

Cross-species stromal signaling programs human embryonic stem cell differentiation.

Taylor RA, Risbridger GP.

Differentiation. 2014 Jan-Feb;87(1-2):76-82. doi: 10.1016/j.diff.2014.01.003. Epub 2014 Feb 13. Review.

PMID:
24530222
44.

DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation.

Pellacani D, Kestoras D, Droop AP, Frame FM, Berry PA, Lawrence MG, Stower MJ, Simms MS, Mann VM, Collins AT, Risbridger GP, Maitland NJ.

Cell Death Differ. 2014 May;21(5):761-73. doi: 10.1038/cdd.2013.202. Epub 2014 Jan 24.

45.

Hedgehog signaling is active in human prostate cancer stroma and regulates proliferation and differentiation of adjacent epithelium.

Wilkinson SE, Furic L, Buchanan G, Larsson O, Pedersen J, Frydenberg M, Risbridger GP, Taylor RA.

Prostate. 2013 Dec;73(16):1810-23. doi: 10.1002/pros.22720. Epub 2013 Sep 16.

PMID:
24105601
46.

Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.

McGrath MJ, Binge LC, Sriratana A, Wang H, Robinson PA, Pook D, Fedele CG, Brown S, Dyson JM, Cottle DL, Cowling BS, Niranjan B, Risbridger GP, Mitchell CA.

Cancer Res. 2013 Aug 15;73(16):5066-79. doi: 10.1158/0008-5472.CAN-12-4520. Epub 2013 Jun 25.

47.

A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors.

Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM; Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP.

Sci Transl Med. 2013 May 29;5(187):187ra71. doi: 10.1126/scitranslmed.3005688.

48.

A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer.

Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, Sieh S, Pedersen JS, Norden S, Frydenberg M, Grummet JP, Pook DW; Australian Prostate Cancer BioResource, Stirzaker C, Clark SJ, Lawrence MG, Ellem SJ, Hutmacher DW, Risbridger GP.

Biomaterials. 2013 Jul;34(20):4777-85. doi: 10.1016/j.biomaterials.2013.03.005. Epub 2013 Apr 2.

PMID:
23562048
49.

A preclinical xenograft model of prostate cancer using human tumors.

Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW, Frydenberg M; Australian Prostate Cancer BioResource, Papargiris MM, Niranjan B, Richards MG, Wang H, Collins AT, Maitland NJ, Risbridger GP.

Nat Protoc. 2013 May;8(5):836-48. doi: 10.1038/nprot.2013.043. Epub 2013 Apr 4.

PMID:
23558784
50.

A versatile monoclonal antibody specific to human SERPINB5.

Teoh SS, Wang H, Risbridger GP, Whisstock JC, Bird PI.

Hybridoma (Larchmt). 2012 Oct;31(5):333-9. doi: 10.1089/hyb.2012.0035.

Supplemental Content

Loading ...
Support Center